Managed Entry Agreements and Funding for Expensive Therapies(Pharmaceuticals, Health Economics and Market Access)

管理进入协议与昂贵治疗的资金

药理学

原   价:
671.00
售   价:
537.00
优惠
平台大促 低至8折优惠
发货周期:国外库房发货,通常付款后3-5周到货!
作      者
出  版 社
出版时间
2022年06月24日
装      帧
平装
ISBN
9780367500269
复制
页      码
174
开      本
234 x 156 mm (6.14 x 9.21
语      种
英文
综合评分
暂无评分
我 要 买
- +
库存 50 本
  • 图书详情
  • 目次
  • 买家须知
  • 书评(0)
  • 权威书评(0)
图书简介
Market entry agreements (MEA) for pharmaceuticals have become extremely popular and widespread geographically. Emerging countries that have not yet begun to introduce MEAs are now actively engaged in doing so. This book examines the concept of MEAs, detailing how depreciation of some specific regenerative therapies through intangible asset amortization is unavoidable.The authors provide a historical vision of the development of MEAs with experiences, failures, and successes that have shaped the evolution and place of MEAs in access to pharmaceuticals. They provide an extensive review of MEA typology and propose a new one that is pragmatic and actionable.FEATURES
  • Discusses the affordability of future therapies and the possible challenges for health insurance systems
  • Addresses the practical and applied issue of market access and includes the most up-to-date developments, such as the Pelosi bill
  • Describes the potential paradigm change that will challenge all payers and may question the sustainability of our health care systems
  • Highlights the gradual move from repeated treatment administration to a single administration with the potential for a definite cureManaged Entry Agreements and Funding for Expensive Therapies provides invaluable information to all stakeholders involved in market access and to students in the field.
  • 本书暂无推荐
    本书暂无推荐
    看了又看
    • 上一个
    • 下一个